JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB214194

Anti-JAM-C antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal JAM-C antibody. Suitable for IHC-P and reacts with Rat samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human JAM3 aa 1-100 conjugated to Keyhole Limpet Haemocyanin.

View Alternative Names

UNQ859/PRO1868, JAM3, Junctional adhesion molecule C, JAM-C, JAM-2, Junctional adhesion molecule 3, JAM-3, JAMC

1 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAM-C antibody (AB214194)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAM-C antibody (AB214194)

Immunohistochemical analysis of formalin-fixed and paraffin-embedded rat brain tissue labeling JAM-C with ab214194 at 1/200 dilution, followed by conjugation to the secondary antibody and DAB staining.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Rat

Applications

IHC-P

applications

Immunogen

Synthetic Peptide within Human JAM3 aa 1-100 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

Q9BX67

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Mouse": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol." } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Junctional adhesion molecule-C (JAM-C) is a cell adhesion molecule belonging to the immunoglobulin superfamily also known as JAM3. It has a mass around 37 kDa. JAM-C is present on endothelial cells various immune cells and some epithelial cells. This protein functions mechanically in maintaining tight junctions that control paracellular permeability and are important in cell-to-cell interactions.
Biological function summary

Junctional adhesion molecule-C plays significant roles in leukocyte migration angiogenesis and the maintenance of vascular endothelial barrier function. JAM-C is part of a larger junctional adhesion molecule complex which includes JAM-A and JAM-B that collectively influence these processes. Its expression in tissues such as the heart and brain suggests specialized roles in physiological functions including cardiovascular regulation and CNS barriers.

Pathways

Junctional adhesion molecule-C is an integral component of the leukocyte transmigration and angiogenesis pathways. These pathways collaborate to allow immune cells to pass through vessel walls a fundamental process in immune surveillance and response. Additionally JAM-C interacts with integrins and other adhesion molecules facilitating cellular communication necessary for tissue repair and growth.

Dysregulation of junctional adhesion molecule-C expression associates with inflammatory diseases and cancer. Altered JAM-C levels have implications in autoimmune disorders where abnormal leukocyte extravasation occurs. Its connection to cancer involves interactions with proteins like VE-cadherin contributing to increased tumor angiogenesis and metastasis making it a potential target for therapeutic intervention in these conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Junctional adhesion protein that mediates heterotypic cell-cell interactions with its cognate receptor JAM2 to regulate different cellular processes (PubMed : 11590146, PubMed : 11823489). Plays a role in homing and mobilization of hematopoietic stem and progenitor cells within the bone marrow. At the surface of bone marrow stromal cells, it contributes to the retention of the hematopoietic stem and progenitor cells expressing JAM3 (PubMed : 11590146, PubMed : 24357068). Plays a central role in leukocytes extravasation by facilitating transmigration through the endothelium (By similarity). Plays a role in spermatogenesis where JAM2 and JAM3, which are respectively expressed by Sertoli and germ cells, mediate an interaction between both cell types and play an essential role in the anchorage of germ cells onto Sertoli cells and the assembly of cell polarity complexes during spermatid differentiation (By similarity). Also functions as a counter-receptor for ITGAM, mediating leukocyte-platelet interactions and is involved in the regulation of transepithelial migration of polymorphonuclear neutrophils (PMN) (PubMed : 12208882, PubMed : 15194813). Plays a role in angiogenesis (PubMed : 23255084). Plays a role in the regulation of cell migration (Probable). During myogenesis, it is involved in myocyte fusion (By similarity).. Soluble form of JAM-C. Promotes chemotaxis of vascular endothelial cells and stimulates angiogenesis.
See full target information JAM3

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Hypertension research : official journal of the Japanese Society of Hypertension 48:2218-2233 PubMed40490489

2025

Dark-phase melatonin administration does not reduce blood pressure but induces changes in parameters related to the control of the cardiovascular system in spontaneously hypertensive rats.

Applications

Unspecified application

Species

Unspecified reactive species

Hana Mauer Sutovska,Lubos Molcan,Peter Stefanik,Michal Zeman

Frontiers in pharmacology 12:666790 PubMed34220506

2021

Synergic Neuroprotection Between Hort and Borneol Against Ischemic Stroke by Neurogenesis Modulating Reactive Astrogliosis and Maintaining the Blood-Brain Barrier.

Applications

Unspecified application

Species

Unspecified reactive species

Bin Yu,Yao Yao,Xiaofeng Zhang,Ming Ruan,Zhennian Zhang,Li Xu,Tao Liang,Jinfu Lu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com